Small molecule inhibitors targeting key proteins in the BCR signaling pathway as well as the BCL2-mediated apoptotic pathway have significantly improved clinical outcomes of patients with CLL/SLL. Here, BCL2 is linked to B-cell chronic lymphocytic leukemia.